gene_symbol
SLAMF7
hgnc_id
HGNC:21394
binding_type
antigen recognition
cytotoxicity
YES
cytotoxicity_type
DIRECT
cytotoxicity_mechanism
Elotuzumab binds SLAMF7 on myeloma cells and its Fc engages FcγRIIIa on NK cells, triggering antibody-dependent cellular cytotoxicity (ADCC) with perforin/granzyme release; it also activates NK cells via SLAMF7 to enhance killing.
enzyme_product
Off
epitope
Off
variant
Off
isoform
Off
hla_specific
Off
gated
Off
other_modifier
Expressed on multiple myeloma cells and NK cells; antibody mediates ADCC
trial_id_tar_ref
drug_id_tar_ref
disease_id_tar_ref
nct_id_tar_ref
NCT06158841
disease_id_num_tar_ref
2257
drug_id_num_tar_ref
6037